BSE Live
Apr 02, 16:01Prev. Close
5.23
Open Price
5.79
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of DECIPHER LABS (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Sep 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -4.60 | -1.00 | -0.18 | -0.52 | 0.92 | |
| Diluted EPS (Rs.) | -4.60 | -1.00 | -0.18 | -0.52 | 0.92 | |
| Cash EPS (Rs.) | -4.31 | -0.72 | 0.08 | -0.43 | 3.18 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 4.25 | 8.85 | 9.83 | 10.00 | -46.65 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 4.25 | 8.85 | 9.83 | 10.00 | -46.65 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 0.12 | 0.06 | 0.63 | 1.16 | 48.48 | |
| PBDIT/Share (Rs.) | -0.13 | -0.74 | 0.08 | -0.43 | 3.18 | |
| PBIT/Share (Rs.) | -0.42 | -1.00 | -0.18 | -0.52 | 0.92 | |
| PBT/Share (Rs.) | -4.60 | -1.00 | -0.18 | -0.52 | 0.92 | |
| Net Profit/Share (Rs.) | -4.60 | -1.00 | -0.18 | -0.52 | 0.92 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | -108.04 | -1,284.48 | 13.43 | -36.97 | 6.56 | |
| PBIT Margin (%) | -348.97 | -1,736.90 | -28.09 | -44.71 | 1.90 | |
| PBT Margin (%) | -3,824.40 | -1,736.90 | -28.09 | -44.71 | 1.90 | |
| Net Profit Margin (%) | -3,824.40 | -1,736.90 | -28.09 | -44.71 | 1.90 | |
| Return on Networth / Equity (%) | -108.35 | -11.27 | -1.78 | -5.17 | -1.97 | |
| Return on Capital Employed (%) | -108.35 | -11.19 | -1.77 | -5.15 | 0.35 | |
| Return on Assets (%) | -95.58 | -10.07 | -1.62 | -4.56 | 0.31 | |
| Total Debt/Equity (X) | 0.00 | 0.01 | 0.01 | 0.01 | -0.04 | |
| Asset Turnover Ratio (%) | 2.49 | 0.57 | 5.77 | 10.21 | 16.54 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.71 | 2.08 | 2.88 | 2.30 | 2.65 | |
| Quick Ratio (X) | 0.61 | 0.98 | 1.34 | 1.30 | 1.43 | |
| Inventory Turnover Ratio (X) | 0.19 | 0.05 | 0.43 | 0.89 | 1.27 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 7.35 | 5.32 | 72.05 | 0.04 | -0.14 | |
| EV/Net Operating Revenue (X) | 76.31 | 115.76 | 143.87 | 0.04 | -0.09 | |
| EV/EBITDA (X) | -70.63 | -9.01 | 1,070.64 | -0.11 | -1.39 | |
| MarketCap/Net Operating Revenue (X) | 77.32 | 114.66 | 143.78 | 0.09 | 0.00 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 2.19 | 0.74 | 9.16 | 0.01 | 0.00 | |
| Price/Net Operating Revenue | 77.58 | 115.61 | 144.00 | 0.09 | 0.00 | |
| Earnings Yield | -0.49 | -0.15 | 0.00 | -5.17 | 9.22 |
26.11.2025
DECIPHER LABS Consolidated September 2025 Net Sales at Rs 4.31 crore, down 26.47% Y-o-Y
24.11.2025
DECIPHER LABS Standalone September 2025 Net Sales at Rs 0.09 crore, up 5.01% Y-o-Y
10.06.2025
DECIPHER LABS Standalone March 2025 Net Sales at Rs 0.23 crore, down 93.27% Y-o-Y
03.06.2025
DECIPHER LABS Consolidated March 2025 Net Sales at Rs 3.50 crore, down 66.95% Y-o-Y
26.11.2025
DECIPHER LABS Consolidated September 2025 Net Sales at Rs 4.31 crore, down 26.47% Y-o-Y
24.11.2025
DECIPHER LABS Standalone September 2025 Net Sales at Rs 0.09 crore, up 5.01% Y-o-Y
10.06.2025
DECIPHER LABS Standalone March 2025 Net Sales at Rs 0.23 crore, down 93.27% Y-o-Y
03.06.2025
DECIPHER LABS Consolidated March 2025 Net Sales at Rs 3.50 crore, down 66.95% Y-o-Y
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth